Skip to main content
Premium Trial:

Request an Annual Quote

Bartu Ahiska

Oxford Biodynamics has appointed Bartu Ahiska as senior vice president (commercial) to spearhead commercialization of the company's EpiSwitch technology platform. Ahisku joins OBD from the Knight Cancer Early Detection Advanced Research Center at Oregon Health & Science University in Portland, where he has been the manager of innovation, IP, and and commercialization since 2016. He was a cofounder and remains a non-executive director of Trogenex in San Diego, and was COO and CEO of cloud-computing company Approxy before its acquisition by Numecent.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.